Core Viewpoint - Bank of America Securities reports that Smoore International (06969) experienced an 18% year-on-year increase in revenue for the first half of the year, while after-tax net profit declined by 2.5%, which is roughly in line with expectations [1] Group 1 - The company is expected to see a slight improvement in revenue growth for the full year, but profit margins are anticipated to remain under pressure [1] - Due to the weak profitability of Smoore International, the earnings per share estimates for the next two years have been lowered by 5% and 10% respectively [1] - The target price has been reduced by 6% to HKD 8.7, and the rating has been reiterated as "underperform" [1]

Core Viewpoint - Smoore International (06969) experienced a significant stock price fluctuation, initially rising over 8% before closing up 6.25%, but later falling 5.88% to HKD 22.08, with a trading volume of HKD 683 million [1] Financial Performance - For the first half of 2025, Smoore International reported revenue of RMB 6.013 billion, representing a year-on-year increase of 18.3% [1] - Adjusted profit for the period was RMB 737 million, a decrease of 2.1% year-on-year [1] - Net profit for the period was RMB 492 million, reflecting a significant year-on-year decline of 27.96% [1] Dividend Announcement - In celebration of its fifth anniversary since listing, the board declared an interim dividend of HKD 0.20 per share for the six months ending June 30, 2025, compared to HKD 0.05 per share in the same period last year [1] Analyst Insights - According to a report from Bank of America Securities, the company is expected to see slight improvement in annual revenue growth, but profit margins are anticipated to remain under pressure [1]

Core Viewpoint - Smoore International (06969) experienced a significant stock price fluctuation, initially rising over 8% before closing up 6.25%, but later fell by 5.88% to HKD 22.08 with a trading volume of HKD 683 million [1] Financial Performance - For the first half of 2025, Smoore International reported revenue of RMB 6.013 billion, representing a year-on-year increase of 18.3% [1] - Adjusted profit for the period was RMB 737 million, a decrease of 2.1% year-on-year [1] - Net profit for the period was RMB 492 million, reflecting a significant year-on-year decline of 27.96% [1] Dividend Announcement - In celebration of its fifth anniversary since listing, the board declared an interim dividend of HKD 0.20 per share for the six months ending June 30, 2025, compared to HKD 0.05 per share in the same period last year [1] Analyst Insights - According to a report from Bank of America Securities, the company is expected to see slight improvement in annual revenue growth, but profit margins are anticipated to remain under pressure [1]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6]. Core Insights - The company reported a revenue of 60.13 billion yuan for the first half of 2025, representing an 18.3% year-on-year growth. Gross profit reached 22.44 billion yuan, up 16.6%, with a gross margin of 37.3%, slightly down by 0.5 percentage points. However, net profit decreased by 28.0% to 4.92 billion yuan, and adjusted net profit was 7.37 billion yuan, down 2.1% [1][5]. - The company's self-owned brand business, primarily from electronic vapor products and vapor beauty products, generated 12.74 billion yuan in revenue, a 14.1% increase, accounting for 21.2% of total revenue. The European market contributed 10.69 billion yuan, up 15.1%, while the U.S. market saw a decline of 6.7% to 1.74 billion yuan. Notably, the Chinese market surged by 2595.2% to 306.18 million yuan, driven by the sales of the vapor beauty product "Lan Zhi" [2][3]. - The company is experiencing a recovery in its vapor electronic cigarette business, supported by stricter regulations against non-compliant products in global markets. This regulatory environment is expected to sustain growth in both self-owned brand and enterprise client businesses [3][4]. Segment Summaries - **HNB Products**: The company successfully supported strategic clients in launching the high-end HNB product Hilo series, which will be launched nationwide in Japan in September 2025. The company is committed to ongoing R&D in HNB products to address user pain points [4]. - **Vapor Medical**: The subsidiary, Chuan Si Bio, is focused on developing leading generic drugs for asthma and COPD in the U.S. and Europe, with plans for further collaboration with international pharmaceutical companies [4]. - **Vapor Beauty**: The "Lan Zhi" home beauty device has surpassed 10,000 users, and the professional equipment has received Class II medical device certification, with over 100 private institutions procuring it [4]. Profit Forecast and Investment Recommendations - The company is positioned as a global leader in vapor technology solutions, with increasing competitive advantages. The report anticipates significant contributions from HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 set at 14.72 billion, 19.79 billion, and 26.63 billion yuan, respectively, reflecting year-on-year growth rates of 34.40% and 34.60% for 2026 and 2027 [5].

Group 1 - The core viewpoint of the article highlights the recent stock performance of Smoore International, which experienced a decline of 4.94% on August 22, trading at HKD 22.3 per share with a transaction volume of HKD 540 million [1] - Smoore International Holdings Limited is recognized as a global leader in aerosol technology solutions, employing nearly 20,000 staff and operating 9 research institutes worldwide, supported by a research and development team of over 1,000 [1] - As of June 30, 2021, the company has filed a total of 2,612 patents and 566 trademarks globally, with 1,272 patents and 360 trademarks granted, alongside multiple national and international certifications and honors [1] Group 2 - For the mid-term of 2025, the company plans to distribute a dividend of HKD 0.2 per share, with the ex-dividend date set for September 5, 2025, and the payment date on September 25, 2025, as per the board's proposal [2]

Core Viewpoint - The company reported strong revenue growth in the first half of the year, driven by regulatory enforcement in the US and Europe, while net profit declined due to increased non-cash share-based payments and rising operational costs [1][2][3] Financial Performance - The company achieved revenue of 6.013 billion yuan, a year-on-year increase of 18.3%, while net profit was 492 million yuan, down 28.0% year-on-year [1] - Adjusted net profit was 737 million yuan, a slight decrease of 2.1% year-on-year, aligning with previous forecasts [1] - The gross profit margin for the first half was 37.3%, a decrease of 0.5 percentage points year-on-year [3] Business Segments - The To B business segment generated revenue of 4.939 billion yuan, up 19.5% year-on-year, with significant growth in Europe and other markets [2] - The To C business segment reported revenue of 1.274 billion yuan, a year-on-year increase of 14.1%, with notable performance from the "Lan Zhi" brand in China [2] - The HNB (Heat-not-Burn) business is progressing as planned, with product launches in Serbia and Sendai, Japan, expected to expand further [3] Cost and Expenses - The increase in share-based payments contributed to a rise in management expense ratios, while R&D expense ratios decreased [3] - Distribution and sales expenses rose due to increased marketing efforts for the company's own brands and global expansion [3] Future Outlook - The company anticipates continued recovery in its core vaporization business, supported by improving regulatory frameworks in the US and Europe [1][2] - The introduction of new HNB products is expected to open a second growth curve for the company [3] Profit Forecast and Valuation - Profit forecasts have been adjusted downward due to the impact of share-based payments, with expected net profits for 2025-2027 at 1.007 billion, 1.830 billion, and 2.559 billion yuan respectively [3] - The target price for the company's stock is set at 27.00 HKD, based on a 71 times PE ratio for 2026 [3]

Core Viewpoint - The company reported its 2025 first-half results, showing revenue growth driven by effective enforcement actions against non-compliant products and the rapid launch of innovative compliant products to meet market demand [1] Group 1: Financial Performance - In H1 2025, the company achieved revenue of 6.013 billion yuan, a year-on-year increase of 18.3%, while net profit was 492 million yuan, a decrease of 28.0% [1] - Adjusted net profit was 737 million yuan, down 2.1% year-on-year [1] - The gross margin for H1 2025 was 37.3%, a decrease of 0.5 percentage points year-on-year [2] Group 2: Business Segments - The self-owned brand business generated revenue of 1.274 billion yuan, up 14.1% year-on-year, with significant growth in Europe and other regions [1] - Revenue from the HNB (Heated Not Burned) business is expected to grow significantly, with the global market projected to reach approximately 66.86 billion USD by 2029, growing at a CAGR of about 10.1% from 2024 to 2029 [2] Group 3: Strategic Initiatives - The company is increasing marketing investments and enhancing employee incentives to solidify long-term competitive advantages [2] - The company is focusing on supporting strategic clients in launching high-end HNB product series in key markets, with positive early consumer feedback [2] Group 4: Future Outlook - The company expects revenue growth for 2025-2027 to be 13.45 billion, 15.49 billion, and 17.66 billion yuan respectively, with year-on-year growth rates of 14%, 15%, and 14% [3] - The company anticipates a significant increase in net profit in 2026 and 2027, with projections of 1.812 billion and 2.595 billion yuan respectively [3]

Summary of Smoore International's Conference Call Company Overview - **Company**: Smoore International - **Industry**: Vapor Technology and Tobacco Industry Key Financial Performance - **Revenue**: In the first half of 2025, Smoore International reported revenue of 9 billion yuan, a year-on-year increase of 19.5% [2][4] - **Regional Performance**: - European market revenue growth reached 38% due to compliance product sales following a one-time ban [2][4] - Revenue growth in the US and China was 1.5% and -6.1%, respectively [2][4] - **Profit**: The company achieved a profit of 4.92 billion yuan, a decline of 28% year-on-year, primarily due to increased stock incentive amortization, administrative expenses, and marketing costs [2][5] - **Adjusted Net Profit**: Adjusted net profit was 7.37 billion yuan, down 2.1% year-on-year, but actual growth was noted after excluding a 70 million yuan tax impact from OECD's dual pillar international tax [2][5] Future Outlook - **Second Half Expectations**: Smoore International anticipates maintaining double-digit revenue growth in the second half of 2025, with profits expected to remain flat [2][6] - **Key Focus Areas**: - Sales performance of HNB products in Japan in September [2][6] - Progress of British American Tobacco's Halo product launch in Europe, which has the largest marketing budget in its history [2][6] Emerging Business Developments - **Medical Vaporization**: The company is successfully collaborating with major pharmaceutical companies, aiming for FDA approval within the next two to three years [2][7] - **Beauty Vaporization**: The Lancome brand achieved revenue of 31 million yuan in the first half of the year, with expectations of significant profit contributions in the next two years [2][7] Industry Perspective - **Market Position**: Smoore International is viewed as a leader in vapor technology, with a positive outlook on the transformation of the tobacco industry, particularly in the HNB segment [3][8] - **Traditional Business Recovery**: The traditional business is showing signs of recovery, especially in the European market, which has exceeded expectations [2][8] - **Future Profit Contribution**: HNB business is projected to contribute over 1 billion yuan in profit increment next year, while other emerging businesses will take two to three years to reflect in financial statements [2][8]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Insights - The company reported a revenue of 6.013 billion yuan for H1 2025, representing a year-on-year increase of 18.3%, while net profit decreased by 28.0% to 492 million yuan [1] - The company's proprietary brand business revenue reached 1.274 billion yuan in H1 2025, up 14.1% year-on-year, with significant growth in the European market [2] - The company is experiencing a recovery in the European vaping market, with a strong response to new compliant products, while the U.S. market is expected to stabilize due to tightening regulations [3] - The company is optimizing R&D expenses and maintaining stable operational capabilities, with a gross margin of 37.3% and an adjusted net profit margin of 12.3% in H1 2025 [4] Financial Performance Summary - For 2025-2027, the company is projected to achieve net profits of 1.228 billion yuan, 2.013 billion yuan, and 3.058 billion yuan, with corresponding P/E ratios of 103.4X, 63.1X, and 41.6X [4] - The total revenue is expected to grow from 11.799 billion yuan in 2024 to 19.291 billion yuan in 2027, with a year-on-year growth rate of 18% in 2027 [6] - The company's cash flow from operating activities is projected to improve significantly, reaching 2.680 billion yuan by 2027 [9]

Group 1 - As of August 21, SMOORE International (06969.HK) closed at HKD 23.460, up 6.25% from the previous trading day, with an intraday high of HKD 24.120, marking a nearly one-year high [1] - On that day, the net inflow of funds was HKD 165.748 million, with no specific data provided for inflows and outflows [1] Group 2 - SMOORE International Holdings Limited was established in 2009 and is a global leader in providing atomization technology solutions, owning one proprietary brand (VAPORESSO) and three technology brands (FEELM, CCELL, METEX) [2] - The company is headquartered in Bao'an District, Shenzhen, with nearly 20,000 employees [2] - SMOORE was officially listed on the Hong Kong Stock Exchange on July 10, 2020, under the stock code HK6969 [2] - The company places a strong emphasis on technological innovation and research and development, with a total of 9 research institutes globally and a research team of over 1,000, accounting for nearly half of its non-production staff [2] - As of June 30, 2021, SMOORE had applied for a total of 2,612 patents and 566 trademarks, with 1,272 patents and 360 trademarks granted [2] - The company has received various certifications and honors, including "National CNAS Laboratory Certification," "International UL Safety Laboratory Certification," "National High-tech Enterprise Certification," "ISO9001 Quality System Certification," "GSV Factory Safety Certification," "AEO Advanced Customs Certification," and "Shenzhen Bao'an District Mayor's Quality Award" [2]